

Accepted Manuscript

Ranking the harm of non-medically used prescription opioids in the UK

Dr. Jan van Amsterdam, Lawrence Phillips, Graeme Henderson, James Bell, Owen Bowden-Jones, Richard Hammersley, John Ramsey, Polly Taylor, Annette Dale-Perera, Jan Melichar, Wim van den Brink, David Nutt



PII: S0273-2300(15)30065-9

DOI: [10.1016/j.yrtph.2015.09.014](https://doi.org/10.1016/j.yrtph.2015.09.014)

Reference: YRTPH 3393


To appear in: *Regulatory Toxicology and Pharmacology*

Received Date: 9 September 2015

Accepted Date: 10 September 2015

Please cite this article as: van Amsterdam, J., Phillips, L., Henderson, G., Bell, J., Bowden-Jones, O., Hammersley, R., Ramsey, J., Taylor, P., Dale-Perera, A., Melichar, J., van den Brink, W., Nutt, D., Ranking the harm of non-medically used prescription opioids in the UK, *Regulatory Toxicology and Pharmacology* (2015), doi: 10.1016/j.yrtph.2015.09.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

1
2 **Ranking the harm of non-medically used prescription opioids in the UK**

3
4 Jan van Amsterdam¹, Lawrence Phillips², Graeme Henderson³, James Bell⁴, Owen Bowden-
5 Jones⁵, Richard Hammersley⁶, John Ramsey⁷, Polly Taylor⁸, Annette Dale-Perera⁹, Jan
6 Melichar¹⁰, Wim van den Brink¹, David Nutt¹¹

7
8 Department of Psychiatry, Academic Medical Centre, University of Amsterdam, Amsterdam, the
9 Netherlands¹

10 Department of Management, London School of Economics and Political Science, London, UK²

11 School of Physiology & Pharmacology, University of Bristol, Bristol, UK³

12 Kings College London, London, UK⁴

13 Faculty of Medicine, Department of Medicine, Imperial College London, London, UK⁵

14 Department of Psychology, University of Hull, Hull, UK⁶

15 TICTAC Communications Ltd, St George's University of London, London, UK⁷

16 Taylor Monroe, Ely, UK⁸

17 NHS, London, UK⁹

18 School of Clinical Sciences, University of Bristol, Bristol, UK¹⁰

19 Centre for Neuropsychopharmacology, Imperial College London, London, UK¹¹

20
21 **Correspondence:** Dr. Jan G.C. van Amsterdam, Department of Psychiatry, Academic Medical

22 Centre, University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands

23 Email: jan.van.amsterdam@amc.uva.nl

24

1 **Running head:** ranking prescription opioids

2

3 **Key words:** opioids, MCDA, risk assessment, ranking, prescription drugs, harm, street heroin

4

5 **Word count:** 5159, including references

6

ACCEPTED MANUSCRIPT

1 SUMMARY

2 A panel of nine experts applied multi-criteria decision analysis (MCDA) to determine the relative
3 overall harm to users and harms to others of street heroin (injected and smoked) and eleven non-
4 medically used prescription opioids. The experts assessed harm scores for each of the 13 opioids
5 on each of 20 harm criteria, weighted the criteria and explored the resulting weighted harm scores
6 for each opioid.

7 Both forms of heroin scored very high: overall harm score of 99 for injected heroin and 72 for
8 smoked heroin on a scale of 0-100. The main feature that distinguishes both forms of street
9 heroin use is that their harm to others is more than five times that of the other eleven opioids. The
10 overall harm score of fentanyl (including injection of fentanyl extracted from patches) and
11 diamorphine (medically prescribed form of heroin) was 54 and 51, respectively, whereas that of
12 orally used opioids ranged from 32 (pethidine) to 11 (codeine-containing pharmaceuticals).
13 Injected street heroin, fentanyl and diamorphine emerged as most harmful to users, with the latter
14 two very low in harm to others. Pethidine, methadone, morphine and oxycodone are also low in
15 harm to others, while moderate in harm to users.

16 We conclude that the overall harms of non-medically used prescription opioids are less than half
17 that of injected street heroin. These data may give a basis for precautionary regulatory measures
18 that should be considered if the rising trend in non-medical use of prescription opioids were to
19 become evident in the UK.

1 INTRODUCTION

2 Prescription opioids are non-medically used for a variety of reasons, mostly because they give
3 benefits ranging from pain relief to euphoria. For non-medical use a variety of definitions are
4 used in the studies described in literature. Here, after discussion, non-medical use was defined as
5 “taking too much and/or too long” for whatever reason, where too much and too long are defined
6 as discordant with the usual medical use of the drug. This definition encompasses use not
7 prescribed, or beyond that prescribed, as well as use with no medical sanction or intention. The
8 type of opioid use that was evaluated by the experts in the current study was ‘non-medical or
9 illicit use’ of prescription opioids.

10 Over the past two decades in the U.S. and to a lesser extent in Canada, the use of opioid
11 analgesics, especially oxycodone (OxyContin), increased 10 to 14-fold (Manchikanti et al.,
12 2012). This increase followed a liberalization of the law in prescribing opioid analgesics by the
13 Federation of State Medical Boards, which encouraged doctors to be more proactive in
14 identifying and treating chronic pain (FSMB, 1998). As a consequence, in the U.S., the number
15 of opioid prescriptions delivered by pharmacies between 1991 and 2011 increased from 76 to 219
16 million (Volkow, 2014). Furthermore, between 1999 and 2008, the four-fold increase in the
17 prescribing of opioid analgesics was paralleled by a four-fold increase in both the number of
18 opioid dependent people (from 2.2% to 9.8%) and the number of fatal opioid related overdoses
19 (CDC, 2011). In the U.S. in 2012, 75% of all fatal incidents with pharmaceutical products were
20 related to opioids (Jones et al., 2013) and 420,000 visits to the emergency departments were
21 opioid related (SAMHSA, 2013). Therefore, the increased misuse of opioid analgesics and the
22 clear increase in opioid-related morbidity and mortality in the U.S. was labelled by the CDC as
23 one of the top five health threats for 2014 (CDC, 2013).

24 In the past two decades, the use of opioid analgesics also significantly increased in Europe

1 (DCAMC, 2012, Ruscitto et al., 2014, Zin et al., 2014, Schubert et al., 2013, Bandieri et al.,
2 2009, Garcia del et al., 2008, Poulsen et al., 2013, Fredheim et al., 2010, Hawton et al., 2012,
3 NHS, 2011), but it is unlikely that in the UK and elsewhere in Europe the non-medical use of
4 prescription opioids will become as prevalent as in the U.S. (Fischer et al., 2014, Weisberg et al.,
5 2014). In the U.S. opioids are widely available as they are often given by family and friends or
6 can be obtained by "doctor shopping" or purchased from semi-legal and illegal pain clinics. For a
7 review about the misuse of prescription opioids, see van Amsterdam and van den Brink (2015).

8 In comparison, access to more potent opioid medications for pain relief in the UK seems to be
9 limited due to the stricter legislation and regulation and the efficient control of both the
10 prescription and the delivery of opioid analgesics using electronic patient records. However, it
11 has been shown that 30% of UK patients with opiate substitution prescriptions sold, gave away or
12 swapped their medication (Dale-Perera et al., 2012), explaining the relatively high misuse of
13 diverted opioid substitution medication amongst drug using populations in England and Scotland,
14 mainly by out-of-treatment opioid users (Stöver, 2012), compared to other drug using populations
15 in European countries (Dale-Perera et al., 2012). The increased use of opioid analgesics in Europe
16 was not accompanied by an increase in the misuse of these drugs or an increased number of fatal
17 incidents. While in the U.S. the use of opioids between 1999 and 2008 (in morphine equivalents
18 per person per year) increased from 350 to 700 and the number of drug deaths doubled from 6 to
19 12 per 100,000, the use of opioids in Britain increased from 100 to 300, but the number of drug
20 deaths remained stable at 6 per 100,000 (Weisberg et al., 2014). These data suggest that in the
21 U.S. the widespread use of opioid analgesics has increased the prevalence of opioid abuse,
22 whereas in the UK misuse of prescribed opioids is predominantly misuse of formulations
23 prescribed as heroin substitutes, which tend to be less risky than misuse of heroin and other street
24 opiates.

1 If the non-medical use of prescription opioids were to increase in Europe, this would be from a
2 relatively high baseline, so future precautionary regulatory responses may be needed. Therefore,
3 the relative overall harm of eleven non-medically used opioid analgesics was evaluated, using
4 street heroin as a reference. This is important as the problems in the U.S. and Canada occur
5 mainly with three specific prescription opioids: hydromorphone, oxycodone and fentanyl (Fischer
6 et al., 2014).

7

8 **METHOD**

9 Nine experts with expertise in either drug addiction or pain treatment (8 from the UK, 1 from the
10 Netherlands and all listed as authors of this paper) were invited to take part in this assessment by
11 DrugScience.org.uk (formerly known as the Independent Scientific Committee on Drugs or
12 ISCD). The experts' specialisms included addiction, substance abuse, addiction psychiatry, health
13 psychology, pharmacology, psychopharmacology, toxicology and veterinary science.

14 The experts attended a two-day facilitated workshop (Phillips, 2007) to assess the actual and
15 potential harms related to the 'non-medical or illicit use' of eleven prescription opioids for
16 whatever reason they were used. In addition, injected and smoked street heroin were evaluated
17 for comparison. Illicit or non-medical use of opioids can create harms to users and harms to
18 others, a distinction that had been used before in the assessment of the overall harm of alcohol,
19 tobacco and a number of illicit drugs (van Amsterdam et al., 2010, van Amsterdam et al., 2015,
20 Nutt et al., 2010).

21 All experts were guided by the facilitator (LP) through the methodology and the principles of
22 multi-criteria decision analysis (MCDA) as they constructed a model of overall harm (Nutt et al.,
23 2010, Nutt et al., 2014). The 16 criteria used in these studies were taken from the Nutt et al. 2010
24 study [25] as a starting point. However, the criteria 'Specific impairment in mental functioning',

1 'Injury', 'Environmental damage' and 'International damage' were very slightly modified to
2 reflect the narrower scope of the current study. In addition, four new criteria were used covering
3 the concerns of the expert group related specifically to opioids: 'drug interactions': extent to
4 which this drug could interact with other drugs to increase harm; 'tolerance': the risk of overdose
5 death following loss of tolerance after abstinence or greatly reduced use; 'availability': extent and
6 ease of obtaining a supply; 'altered prescribing': inhibition of clinically indicated prescribing due
7 to concerns regarding the potential for dependence and diversion. The 20 criteria were clustered
8 under five subheadings covering the following domains: (1) physical, (2) psychological and (3)
9 social harm to users, and (4) physical and (5) social harm to others (cf. Fig. 1). Each criterion was
10 carefully explained to the experts by the facilitator which enabled them to evaluate all opioids in
11 a consistent and meaningful way.

12 The following 13 opioids were selected for ranking: injected street heroin, smoked heroin,
13 transdermal fentanyl (including injected fentanyl extracted from patches), pharmaceutical grade
14 injectable diamorphine usually prescribed for treatment of heroin dependence pethidine,
15 methadone, morphine, oxycodone, buprenorphine, tramadol, suboxone (buprenorphine +
16 naloxone), codeine + dihydrocodeine, and compound codeine products. The routes of
17 administration considered included oral, snorting, chewing (patches) or i.v. injection.

18

19 **Scoring principles**

20 The experts scored the criteria directly one by one following the harm tree shown in Figure 1
21 from top to bottom. The facilitator ensured that all viewpoints were aired, judgements were
22 backed with data if available, and bias was minimised by selecting the most harmful drug for
23 each effect and making assessments (e.g., by applying the 'think, speak, debate' sequence of the
24 nominal group technique (Gustafson et al., 1973), which prevents each participant from

1 anchoring their judgement on that of the first person to speak). Per criterion each expert had first
2 to consider his/her score together with an argument before sharing the score with the group. After
3 sharing the scores and their subsequent justifications the final integral score of the expert group
4 was obtained via consensus. This procedure applied both to harm scores as well as to the rating of
5 weighting factors. In making their judgements, participants frequently referred to published data,
6 which were discussed for their representativeness and quality, and debated in light of experience
7 with users. This enabled the group to construct consensus harm scores that represented the
8 participants' collective judgement in light of the evidence and available experience. Occasional
9 marked disagreements were noted and tested in sensitivity analyses. This scoring process is
10 specifically designed to minimise bias (Phillips, 2007).

11

12 **Scoring procedure**

13 First, the most harmful opioid on a given criterion was identified and agreed by the group. That
14 opioid (and any others deemed equally most harmful) was given a harm value of 100, with zero
15 representing no harm; these two points established a ratio scale. Second, each of the remaining
16 opioids was assigned a harm value as a percentage representing the ratio of judged harm
17 compared to the most harmful opioid on the criterion (e.g., an opioid judged to be half as harmful
18 as the most harmful one was given a harm value of 50).

19

20 **Weighting the effect scales**

21 Weight factors were given to each harm criterion to weight the relative importance of each harm
22 criterion to the overall harm of the 13 opioids. This was accomplished by assessing a separate
23 swing-weight (scale 0-100) for each of the criteria, the swing from no harm at all to the most
24 harmful drug on a given criterion. After the weights have been normalised so they sum to 100

1 over all 20 criteria (which preserves their original ratio to one another), the weights are known as
2 'cumulative weights' and represent the difference in judged harm between no harm and the most
3 harmful opioid on each effect. The harm score for an opioid on a given effect scale is multiplied
4 by the cumulative weight for the scale, and those products are summed over the 20 criteria,
5 giving an overall weighted preference score for each opioid.

6

7 **Sensitivity analysis**

8 Finally, the group explored the results and conducted sensitivity analyses to determine the extent
9 to which uncertainty in the data and differences of opinion could change the overall ordering of
10 opioids.

11

12 **RESULTS**

13 **Ranking the opioids**

14 Table 1 shows the cumulative weights associated with each criterion. Note that 16 of the 20
15 criteria each contribute 3% to 9% of the total weight with the highest values for Drug specific
16 mortality, Tolerance, Crime and Economic costs. Drug related impairment of functioning,
17 availability, altered prescribing and environmental damage together contribute only 3.6%.

18 Considering the recent widespread misuse of prescription opioids in Canada and the U.S., it
19 should be highlighted here that the availability of opioids was scored 100 for codeine compounds
20 (OTC; freely available in pharmacies), 90 for injected and smoked heroin and 50 for methadone.
21 The remaining opioids were scored below 30. As stated above, data from England and Scotland
22 indicate that illicit methadone and buprenorphine diverted from prescriptions are readily available
23 in the illegal drug supply system. Moreover, the weight factor for availability was only 0.9.

24 A graphical presentation of the individual contributions of weighted scores of the 13 opioids for

1 the 20 effects (260 scores) is complex and not legible in a grey-scale display so only the overall
2 score of harm to others and harm to users is presented in Figure 2. Note that the sum of the
3 cumulative weights for the 11 harm scales for users is 60%, and is 40% for the 9 harm scales for
4 others.

5 The ranking of the opioids in Figure 2 clearly shows that injected street heroin and smoked street
6 heroin are the most harmful of these 13 opioids. Injected heroin was scored 100, most harmful,
7 on 11 of the 20 harm criteria, while although smoked heroin scored 100 on only four harm
8 criteria, it scored 70 or above on 10 additional criteria. The main feature that distinguishes both
9 heroin opioids from all the other opioids is that street heroin is over five times more harmful to
10 others. The other 11 opioids are all much lower in their harm to others (value below 6.6 on the
11 scale from 0 to 100), while varying in their harms to users.

12 Injected heroin, fentanyl + and diamorphine emerged as most harmful to users, mainly because
13 these three opioids are dosed intravenously which has a high risk of harm from overdosing during
14 non-medically supervised use. Similarly, smoked heroin is considered less harmful for the user
15 than injected heroin, because with smoking the dose can be titrated and tends to be limited by the
16 user's degree of intoxication. Pethidine, methadone, morphine and oxycodone were ranked as
17 lower in harm to others, while moderate in their harm to users. The remaining five opioids are
18 less potent opioid agonists (buprenorphine, tramadol, suboxone, codeine comb. and codeine) that
19 are all lower in harm to users and in harm to others. The small 1-point difference between
20 compound codeine products and codeine resulted from markedly different characteristics:
21 compound codeine was considered as more harmful on drug specific damage to the users (due to
22 the potential for paracetamol overdose), whereas codeine was more harmful mainly because of its
23 higher tolerance.

24 Plotting the harm to users against the harm to others (Figure 3) clearly indicates that smoked and

1 injected heroin were scored as the most harmful opioids for others (appearing in the right upper
2 quadrant) while fentanyl + and diamorphine are equally harmful for users, but much less harmful
3 to others (right lower quadrant).

4

5 **Sensitivity analyses**

6 Because street heroin is the most harmful opioid on harm to the user and on harm to others, it
7 maintains its position as the overall most harmful drug whatever the weight on users or others.
8 All other opioids became more harmful overall as the weight on the harm to users was increased,
9 whereas only smoked heroin became less harmful with more weight on the harm to users. It
10 appeared that unrealistically large changes for a few of the harm criteria were required to make a
11 serious difference, implying that the model is very robust to differences in the judgements about
12 the weights on the individual harm criteria. However, a few opioids showed substantial changes
13 in their ranking when the weights on certain criteria were increased. Compound codeine was
14 particularly susceptible: increasing the weight on 'drug specific damage' or on 'availability'
15 caused compound codeine to move up the rank order: the more weight, the higher the rank.
16 Diamorphine was especially sensitive to the weight on 'altered prescribing'; increasing the
17 weight on that harm to a little more than 30% moved diamorphine to the most harmful position
18 after injected street heroin.

19 Once the final ranking was obtained and presented, the participants found the overall results to be
20 a reasonable representation of overall harm; they realised that testing their few early differences
21 in judgements would not reveal any substantial change in the overall ordering of the 13 opioids.

22

23 **DISCUSSION**

24 The main finding of this study is that the overall harm of a variety of non-medically used

1 prescription opioids is less than half the overall harm of injected street heroin. For the most part
2 this difference emerges from the high harm that is elicited by the use of (injected and smoked)
3 street heroin. For pethidine, diamorphine and fentanyl+ the harm for the user was at least half as
4 high as injected heroin's user harm, which shows a considerable risk if used non-medically. At
5 the other end of the spectrum, codeine preparations and suboxone (a buprenorphine-naloxone
6 combination) had the lowest overall harm scores.

7 The relative overall harm of a variety of licit and illicit recreational drugs for the user and for
8 others was previously assessed in two independent studies using a similar methodology (Nutt et
9 al., 2010, van Amsterdam et al., 2015). The set of substances in these studies held three drugs in
10 common with the present study i.e. heroin, methadone and buprenorphine. Pearson correlation
11 coefficients of 0.90 to 0.98 for input scores on each of the 16 criteria these two studies and the
12 present study held in common were calculated, providing substantial support for the reliability
13 and validity of scores generated by the groups, at least for the three opioids considered in each
14 analysis. Apparently, the group deliberation and discourse provided scores for these three
15 substances that were consistent and replicable.

16 Process validity derives from the soundness of the social process, i.e. decision conferencing.
17 Research on decision conferences (Schilling et al., 2007, Chun, 1992, McCartt and Rohrbaugh,
18 1995, McCartt and Rohrbaugh, 1989) and group workshops (Franco and Montibeller, 2015,
19 Phillips, 2011, Schilling et al., 2007) has identified four features that contribute to validity:
20 competence of the experts (Shanteau, 1992), diversity of perspectives in the group (Shanteau,
21 2001), impartial facilitation by a facilitator who guides the process but does not contribute to
22 content (Phillips, 2007), and development on-the-spot of a model that is based on sound theory
23 (Regan-Cirincione, 1994), in this case, decision theory (Dodgson et al., 2000, Keeney and Raiffa,
24 1976). All of these factors were applied, as far as was practically possible, in designing and

1 conducting the decision conference that was used for this study.

2 It should be noted here that while the magnitude of the harm for the different criteria can be
3 informed by data, the magnitude of weighting factors is not based on data and remains
4 exclusively a matter of judgement. On the other hand, however, the comparison of unweighted
5 overall harm scores can be misleading and one should remain careful not to over-interpret the
6 findings. Finally, we would like to mention that the applied MCDA approach has been criticised
7 (Caulkins et al., 2011). Caulkins et al. (2011) proposed an alternative approach that also included
8 the benefits of the different substances. However, Caulkins' approach probably makes it even
9 more difficult to establish a one-number estimate for the (net) harm of substances and the validity
10 of his approach is unknown. Moreover, it should be noted that in contrast to the risk-benefit
11 evaluation of pharmaceutical compounds, the score in drug evaluation is only meant as a measure
12 of harm because in recreational drug use there is no illness and no potential clinical benefit.

13 The present assessment corroborated the low availability of prescription opioids in the UK
14 (except for codeine), considering the low scores on the criterion 'availability'. Secondly, both in
15 the U.S. and the UK opioid painkillers and heroin share a common market (Weisberg et al., 2014;
16 Inciardi et al., 2009), but the price of heroin in the U.S. is about 7-8 times higher compared with
17 the UK, which may have prevented or at least retarded the development of an illegal market and
18 misuse of opioid analgesics (Weisberg et al., 2014). For these reasons it would be of interest to
19 repeat this MCDA harm assessment in the USA.

20 This analysis shows there are very significant differences in the relative harms of the various non-
21 medically used opioids. Street heroin whether injected or smoked was ranked as the most harmful
22 opioid in the UK today followed by non-medically used prescription opioids such as diamorphine
23 and fentanyl patches. Unexpectedly, oxycodone turned out to be only moderately harmful. This
24 contrasts with the extensive abuse of this specific prescription opioid in the U.S. and Canada. The

1 explanation could be that oxycodone was “aggressively marketed and highly promoted” in North
2 America (Van Zee, 2009) leading to a more than 20-fold increase in sales in four years, more
3 than all other prescription opioids and much more marketing than is allowed for any opioid in the
4 UK. This illustrates that drug harms are not independent of prevalence of use. The current
5 findings have implications for the provision of pain treatment and could provide a basis for
6 precautionary regulatory measures should these become necessary due to a future increase in
7 non-medical use of prescription opioids. However, such measures should be proportionate and
8 not restrict or obstruct the treatment of chronic pain and heroin dependence.

9 The group finally agreed that it would be of value to include real or perceived benefits of drugs in
10 a future MCDA exercise as it was important to recognise drivers for illicit drug taking including
11 pleasure, pain relief or escape from negative cognitive states. However, it was agreed this would
12 double the length of the exercise and should be the focus of a future decision making exercise
13 provided that funding could be found.

14 **Participants**

15 Experts: James Bell, Owen Bowden-Jones, Annette Dale-Perera, Richard Hammersley, Graeme
16 Henderson, Jan Melichar, John Ramsey, Polly Taylor and Jan van Amsterdam. Facilitators:
17 David Nutt and Lawrence Phillips.

18 **Funding**

19 Funding was provided by an unrestricted educational grant to DrugScience from RB
20 pharmaceuticals.

21
22
23

1 **Declaration of interest:** David Nutt has served on advisory Boards for BMS, Lilly, Shire,
2 Lundbeck, Servier, Pfizer, Reckitt Benkiser, and D&A pharma. He has received speaking
3 honoraria from these companies and also from Janssen, BMS, GSK, and Schering-Plough. He is
4 a member of the Lundbeck International Neuroscience Foundation.

5 Polly Taylor acts as independent consultant in veterinary pharmacology and pharmacokinetics to
6 Abbott Laboratories. Dr Polly Taylor has provided consultancy services for the manufacturer of
7 buprenorphine in the UK (Alstoe Animal Health).

8 Wim van den Brink reports personal fees from Mundipharma, grants from Alkermes, during the
9 conduct of the study; personal fees from Lundbeck, Indivior, D&A Pharma, Novartis, Bioproject,
10 Pfizer, outside the submitted work. The other authors declare no conflict of interest.

1 **Legends to figures**

2

3 **Figure 1.** The 20 harm criteria for prescription opioids. See Nutt et al. 2010 for details.

4

5 **Figure 2.** The opioids ranked by their overall weighted harm scores, with the stacked bar
6 graphs showing the contribution to the overall score of harm to others and harm to users with a
7 cumulative weight of 40.0 and 60.0, respectively. Injected heroin: street heroin taken
8 intravenously; Smoked heroin: smoked street heroin; Fentanyl +: non-medical use of patches,
9 including injection of fentanyl extracted from patches; Codeine Comb.: compound codeine
10 products.

11

12 **Figure 3.** Harms to Others versus Harms to User relative to injected heroin. 1: Injected
13 heroin; 2: Smoked heroin; 3: Fentanyl+; 4: Diamorphine and 5: Pethidine.

1 **References**

- 2 Bandieri, E., Chiarolanza, A., Luppi, M., Magrini, N., Marata, A.M., Ripamonti, C., 2009.
3 Prescription of opioids in Italy: everything, but the morphine. *Ann. Oncol.* 20, 961-962.
- 4 Caulkins, J.P., Reuter, P., Coulson, C., 2011. Basing drug scheduling decisions on scientific
5 ranking of harmfulness: false promise from false premises. *Addiction* 106, 1886-1890.
- 6 CDC., 2011. Centers for Disease Control and Prevention (CDC), Vital Signs: Overdoses of
7 Prescription Opioid Pain Relievers - United States, 1999-2008,
8 <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm>. *MMWR Morb. Mortal.*
9 *Wkly. Rep.* 60, 1487-1492.
- 10 CDC., 2013. Centers for Disease Control and Prevention (CDC). CDC's top ten: 5 health
11 achievements in 2013 and 5 health threats in 2014.
12 [http://blogs.cdc.gov/cdcworksforyou24-7/2013/12/cdc%E2%80%99s-top-ten-5-health-](http://blogs.cdc.gov/cdcworksforyou24-7/2013/12/cdc%E2%80%99s-top-ten-5-health-achievements-in-2013-and-5-health-threats-in-2014/)
13 [achievements-in-2013-and-5-health-threats-in-2014/](http://blogs.cdc.gov/cdcworksforyou24-7/2013/12/cdc%E2%80%99s-top-ten-5-health-achievements-in-2013-and-5-health-threats-in-2014/).
- 14 Chun, K.J., 1992. *Analysis of Decision Conferencing: A UK/USA Comparison*. London: London
15 School of Economics & Political Science.
- 16 Dale-Perera, A., Goulão, J., Stöver, H., 2012. Quality of care provided to patients receiving
17 Opioid Maintenance Treatment in Europe: Results from the EQUATOR analysis. *Heroin*
18 *Addict Relat Clin Probl* 14, 23-38.
- 19 DCAMC., 2012. Drug Control and Access to Medicines Consortium (DCAMC). Opioid
20 consumption chart.<http://ppsg-production.herokuapp.com/chart>.
- 21 Dodgson, J., Spackman, M., Pearman, A., Phillips, L., 2000. *Multi-Criteria Analysis: A Manual*.
22 London: Department of the Environment, Transport and the Regions, republished 2009 by
23 the Department for Communities and Local Government.

- 1 Fischer, B., Keates, A., Buhringer, G., Reimer, J., Rehm, J., 2014. Non-medical use of
2 prescription opioids and prescription opioid-related harms: why so markedly higher in
3 North America compared to the rest of the world? *Addiction* 109, 177-181.
- 4 Franco, L.A. and Montibeller, G., 2015. Facilitated modelling in operational research. *European*
5 *Journal of Operational Research* 205, 489-500.
- 6 Fredheim, O.M., Skurtveit, S., Breivik, H., Borchgrevink, P.C., 2010. Increasing use of opioids
7 from 2004 to 2007: Pharmacoepidemiological data from a complete national prescription
8 database in Norway. *Eur. J. Pain* 14, 289-294.
- 9 FSMB., 1998. Federation of State Medical Boards (FSMB) of the US. Model guidelines for the
10 use of controlled substances for the treatment of pain: A policy document of the
11 Federation of State Medical Boards of the United States, Inc. Dallas, TX, USA.
12 www.medsch.wisc.edu/painpolicy/domestic/model.htm.
- 13 Garcia del, P.J., Carvajal, A., Vilorio, J.M., Velasco, A., Garcia, d.P., V., 2008. Trends in the
14 consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces
15 morphine. *Eur. J. Clin. Pharmacol.* 64, 411-415.
- 16 Gustafson, D.H., Shukla, R.U., Delbecq, A., Walster, G.W., 1973. A comparative study of
17 differences in subjective likelihood estimates made by individuals, interacting groups,
18 Delphi groups, and nominal groups. *Organizational Behavior and Human Performance* 9,
19 280-291.
- 20 Hawton, K., Bergen, H., Simkin, S., Wells, C., Kapur, N., Gunnell, D., 2012. Six-year follow-up
21 of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths:
22 time-series study. *PLoS. Med.* 9, e1001213.
- 23 Jones, C.M., Mack, K.A., Paulozzi, L.J., 2013. Pharmaceutical overdose deaths, United States,
24 2010. *JAMA* 309, 657-659.

- 1 Keeney, R.L. and Raiffa, H., 1976. Decisions With Multiple Objectives: Preferences and Value
2 Tradeoffs. New York: John Wiley, republished in 1993 by Cambridge University Press.
- 3 Manchikanti, L., Helm, S., Fellows, B., Janata, J.W., Pampati, V., Grider, J.S., Boswell, M.V.,
4 2012. Opioid epidemic in the United States. *Pain Physician* 15, ES9-38.
- 5 McCartt, A.T. and Rohrbaugh, J., 1989. Evaluating group decision support system effectiveness:
6 A performance study of decision conferencing. *Decision Support Systems* 5, 243-253.
- 7 McCartt, A.T. and Rohrbaugh, J., 1995. Managerial openness to change and the introduction of
8 GDSS: Explaining initial success and failure in decision conferencing. *Organization*
9 *Science* 6, 569-584.
- 10 NHS., 2011. National Health Service (NHS). National Treatment Agency for Substance Misuse.
11 Addiction to medicine: An investigation into the configuration and commissioning of
12 treatment services to support those who develop problems with prescription-only or over-
13 the-counter medicine. <http://www.nta.nhs.uk/uploads/addictiontomedicinesmay2011a.pdf>.
- 14 Nutt, D.J., King, L.A., Phillips, L.D., 2010. Drug harms in the UK: a multicriteria decision
15 analysis. *Lancet* 376, 1558-1565.
- 16 Nutt, D.J., Phillips, L.D., Balfour, D., Curran, H.V., Dockrell, M., Foulds, J., Fagerstrom, K.,
17 Letlape, K., Milton, A., Polosa, R., Ramsey, J., Sweanor, D., 2014. Estimating the harms
18 of nicotine-containing products using the MCDA approach. *Eur. Addict Res.* 20, 218-225.
- 19 Phillips, L.D., 2007. Decision Conferencing. In: Edwards W, Miles RF, von Winterfeldt D,
20 editors. *Advances in Decision Analysis: From Foundations to Applications*. Cambridge:
21 Cambridge University Press.
- 22 Phillips, L.D., 2011. Group dynamics processes for improved decision making. In: Cochran JJ,
23 editor. *Encyclopedia of Operations Research and Management Science*. New York: John
24 Wiley & Sons.

- 1 Poulsen, K.K., Andersen, S.E., Moreno, S.I., Glintborg, D., Thirstrup, S., Aagaard, L., 2013.
2 General practitioners' and hospital physicians' preference for morphine or oxycodone as
3 first-time choice for a strong opioid: a National Register-based study. *Basic Clin.*
4 *Pharmacol. Toxicol.* 112, 110-115.
- 5 Regan-Cirincione, P., 1994. Improving the accuracy of group judgment: A process intervention
6 combining group facilitation, social judgment analysis, and information technology.
7 *Organizational Behavior and Human Decision Processes* 58, 246-270.
- 8 Ruscitto, A., Smith, B.H., Guthrie, B., 2014. Changes in opioid and other analgesic use 1995-
9 2010: Repeated cross-sectional analysis of dispensed prescribing for a large geographical
10 population in Scotland. *Eur. J. Pain* 19, 59-66.
- 11 SAMHSA., 2013. Substance Abuse and Mental Health Services Administration (SAMHSA),
12 Center for Behavioral Health Statistics and Quality. Highlights of the 2011 Drug Abuse
13 Warning Network (DAWN). Findings on drug-related emergency department visits.
14 <http://archive.samhsa.gov/data/2k13/DAWN127/sr127-DAWN-highlights.htm>.
- 15 Schilling, M.S., Oeser, N., Schaub, C., 2007. How Effective Are Decision Analyses? Assessing
16 Decision Process and Group Alignment Effects. *Decision Analysis* 4, 227-242.
- 17 Schubert, I., Ihle, P., Sabatowski, R., 2013. Increase in opiate prescription in Germany between
18 2000 and 2010: a study based on insurance data. *Dtsch. Arztebl. Int.* 110, 45-51.
- 19 Shanteau, J., 1992. Competence in experts: the role of task characteristics. *Organizational*
20 *Behavior and Human Decision Processes* 53, 252-266.
- 21 Shanteau, J., 2001. What does it mean when experts disagree? In: Salas E, Klein G, editors.
22 *Linding expertise and naturalistic decision making*. Mahwah, N.J.: Lawrence Erlbaum
23 Associates.

- 1 Stöver, H., 2012. Assessing the current state of public-health-related outcomes in opioid
2 dependence across Europe: data from the EQUATOR analysis. *Heroin Addict Relat Clin*
3 *Probl* 14, 51-64.
- 4 van Amsterdam J., van den Brink, W., 2015. The Misuse of Prescription Opioids: A Threat for
5 Europe? *Curr. Drug Abuse Rev.* 8, 3-14.
- 6 van Amsterdam, J.G.C., Nutt, D.J., Phillips, L., van den Brink, W., 2015. European rating of drug
7 harms. *J Psychopharmacol.*
- 8 van Amsterdam, J.G.C., Opperhuizen, A., Koeter, M., van den Brink, W., 2010. Ranking the
9 harm of alcohol, tobacco and illicit drugs for the individual and the population. *Eur*
10 *Addiction Res* 16, 202-207.
- 11 Van Zee, A., 2009. The promotion and marketing of oxycontin: commercial triumph, public
12 health tragedy. *Am. J. Public Health* 99, 221-227.
- 13 Volkow, N.D., 2014. Prescription Opioid and Heroin Abuse. [http://www.drugabuse.gov/about-](http://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2014/prescription-opioid-heroin-abuse)
14 [nida/legislative-activities/testimony-to-congress/2014/prescription-opioid-heroin-abuse.](http://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2014/prescription-opioid-heroin-abuse)
- 15 Weisberg, D.F., Becker, W.C., Fiellin, D.A., Stannard, C., 2014. Prescription opioid misuse in
16 the United States and the United Kingdom: Cautionary lessons. *Int. J. Drug Policy* 25,
17 1124-1130.
- 18 Zin, C.S., Chen, L.C., Knaggs, R.D., 2014. Changes in trends and pattern of strong opioid
19 prescribing in primary care. *Eur. J. Pain* 18, 1343-1351.

Table 1. Cumulative weight of the 20 criteria

Name	Cumulative weight
Drug specific mortality	8.8
Drug related mortality	7.5
Drug specific damage	5.7
Drug related damage	5.7
Drug interactions	5.7
Tolerance	8.8
Dependence	5.7
Drug specific impairment of mental functioning	4.2
Drug related impairment of mental functioning	1.4
Loss of tangibles	3.0
Loss of relationships	3.5
Injury	5.3
Availability	0.9
Crime	8.8
Environmental damage	0.4
Family adversities	7.9
International damage	3.5
Economic cost	8.8
Community	3.5
Altered prescribing	0.9




Figure 1 The 20 harm criteria for prescription opioids. See Nutt et al. 2010 for details.




Figure 2: The opioids ranked by their overall weighted harm scores, with the stacked bar graphs showing the contribution to the overall score of harm to others and harm to users with a cumulative weight of 40.0 and 60.0, respectively. Injected heroin: street heroin taken intravenously; Smoked heroin: smoked street heroin; Fentanyl +: non-medical use of patches, including injection of fentanyl extracted from patches; Codeine Comb.: compound codeine products.




Fig 3. Harms to Others versus Harms to User relative to injected heroin. 1: Injected heroin; 2: Smoked heroin; 3: Fentanyl+; 4: Diamorphine and 5: Pethidine.

Highlights

- If misused, prescription opioids may be harmful.
- The overall harm of injected and smoked street heroin is considerably more harmful than the non-medical use of the most potent prescription opioids fentanyl and diamorphine.
- Precautionary regulatory measures are to be taken if the rising trend in non-medical use of prescription opioids were to become evident in the UK.

ACCEPTED MANUSCRIPT

Data imported from the Hiview3 model of the harm of opioids

Assessed Scores		Weights	Normalised weight:	Inj	heroi	Smoked	Fentanyl	Diamorp	Pethidin	Methadcl	Morphin	Oxycodo	Bupreno	Tramadcl	Suboxone	Codeine	Codeine
TO USER	DRUG SPEC MORT	100	0.0879	100	50	100	100	60	50	50	5	20	30	15	10	10	
	DRUG REL MORT	85	0.0747	100	30	70	10	10	10	10	5	10	5	15	7		
	DRUG SPEC DAMAGE	65	0.0571	100	35	30	20	20	20	20	10	10	10	10	50	10	
	DRUG REL DAMAGE	65	0.0571	100	35	80	80	80	25	25	25	20	5	20	15	5	
	DRUG INTERACTIONS	65	0.0571	100	70	100	100	65	65	65	65	30	10	30	40	30	
	TOLERANCE	100	0.0879	100	80	100	100	20	40	40	40	10	30	10	5	20	
	DEPENDENCE	65	0.0571	100	90	100	100	55	55	50	60	35	35	30	15	25	
	SPEC IMPAIRMENT FUNC	48	0.0422	100	100	100	100	100	50	55	55	10	45	10	15	25	
	REL IMPAIRMENT FUNC	16	0.0141	100	80	100	100	100	80	50	50	40	30	40	10	30	
	LOSS OF RELAT	40	0.0351	100	90	100	100	60	60	40	40	60	20	60	5	20	
	LOSS OF TANGIBLES	34	0.0299	100	70	100	100	80	50	50	55	45	35	45	10	35	
	INJURY	60	0.0527	100	90	10	40	20	40	20	30	10	15	5	5		
	CRIME	100	0.0879	100	100	1	1	1	15	1	1	10	1	5	1	1	
ENVIRONM DAMAGE	5	0.0044	100	5	2	2	2	2	1	1	1	1	1	1	1		
FAMILY ADVERSITIES	90	0.0791	100	85	1	2	1	10	5	2	7	5	3	5	5		
ECONOMIC COST	100	0.0879	100	80	2	3	2	15	3	2	10	2	2	3	2		
INTERNATIONAL DAM	40	0.0351	100	100	0	0	0	0	0	0	0	0	0	0	0		
COMMUNITY	40	0.0351	100	100	1	1	1	7	1	1	5	1	2	1	1		
AVAILABILITY	10	0.0088	90	90	1	1	1	50	5	1	30	20	10	100	20		
ALTERED PRESCRIBING	10	0.0088	0	0	10	100	10	55	30	40	20	20	0	0	5		
Totals	1138	1.0000	99	72	54	51	32	31	26	22	17	15	14	12	11		
Weighted Scores				Injected	Smoked	Fentanyl	Diamorp	Pethidin	Methadcl	Morphin	Oxycodo	Bupreno	Tramadcl	Suboxone	Codeine	Codeine	
TO USER	DRUG SPEC MORT	8.79	4.39	8.79	8.79	5.27	4.39	4.39	0.44	1.76	2.64	1.32	0.88	0.88			
	DRUG REL MORT	7.47	2.24	5.23	0.75	0.75	0.75	0.75	0.75	0.37	0.75	0.37	1.12	0.52			
	DRUG SPEC DAMAGE	5.71	2.00	1.71	1.14	1.14	1.14	1.14	1.14	0.57	0.57	2.86	0.57				
	DRUG REL DAMAGE	5.71	2.00	4.57	4.57	4.57	1.43	1.43	1.43	1.14	0.29	1.14	0.86	0.29			
	DRUG INTERACTIONS	5.71	4.00	5.71	5.71	3.71	3.71	3.71	3.71	1.71	0.57	1.71	2.28	1.71			
	TOLERANCE	8.79	7.03	8.79	8.79	1.76	3.51	3.51	3.51	0.88	2.64	0.88	0.44	1.76			
	DEPENDENCE	5.71	5.14	5.71	5.71	3.14	3.14	2.86	3.43	2.00	2.00	1.71	0.86	1.43			
	SPEC IMPAIRMENT FUNC	4.22	4.22	4.22	4.22	4.22	2.11	2.32	2.32	0.42	1.90	0.42	0.63	1.05			
	REL IMPAIRMENT FUNC	1.41	1.12	1.41	1.41	1.41	1.12	0.70	0.70	0.56	0.42	0.56	0.14	0.42			
	LOSS OF RELAT	3.51	3.16	3.51	3.51	2.11	2.11	1.41	1.41	2.11	0.70	2.11	0.18	0.70			
	LOSS OF TANGIBLES	2.99	2.09	2.99	2.99	2.39	1.49	1.64	1.64	1.34	1.05	1.34	0.30	1.05			
	INJURY	5.27	4.75	0.53	2.11	1.05	2.11	1.05	1.05	1.58	0.53	0.79	0.26	0.26			
	CRIME	8.79	8.79	0.09	0.09	0.09	1.32	0.09	0.09	0.88	0.09	0.44	0.09	0.09			
ENVIRONM DAMAGE	0.44	0.02	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
FAMILY ADVERSITIES	7.91	6.72	0.08	0.16	0.08	0.79	0.40	0.16	0.55	0.40	0.24	0.40	0.40				
ECONOMIC COST	8.79	7.03	0.18	0.26	0.18	1.32	0.26	0.18	0.88	0.18	0.18	0.26	0.18				
INTERNATIONAL DAMAGE	3.51	3.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
COMMUNITY	3.51	3.51	0.04	0.04	0.04	0.25	0.04	0.04	0.18	0.04	0.04	0.07	0.04				
AVAILABILITY	0.79	0.79	0.01	0.01	0.01	0.44	0.04	0.01	0.26	0.18	0.09	0.58	0.18				
ALTERED PRESCRIBING	0.00	0.00	0.09	0.88	0.09	0.48	0.26	0.35	0.18	0.18	0.00	0.00	0.04				
Totals			99	72	54	51	32	31	26	22	17	15	14	12	11		

